RT Journal Article
SR Electronic
T1 Association of CD31 and p53 With Survival of Ovarian Cancer Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 567
OP 576
DO 10.21873/anticanres.13149
VO 39
IS 2
A1 LENE RASK
A1 CLAUS K. HØGDALL
A1 SUSANNE K. KJAER
A1 LISE CHRISTENSEN
A1 ALLAN JENSEN
A1 JAN BLAAKAER
A1 IB JARLE CHRISTENSEN
A1 ESTRID V.S. HØGDALL
YR 2019
UL http://ar.iiarjournals.org/content/39/2/567.abstract
AB Background/Aim: New markers for ovarian cancer are needed. This study aimed to examine the expression of tumour cell p53 and endothelial cell CD31 proteins and correlate them to clinicopathological factors. Patients and Methods: Expression of proteins was immunohistochemically assessed using tissue sections from 585-599 ovarian cancer patients from the Danish MALOVA study. Results: High CD31 expression was found in poorly differentiated tumours (p=0.0006), and high p53 expression was found in poorly differentiated cancers (p<0.0001), high clinical stage (p<0.0001), non-radical surgery (p<0.0001) and high serum CA-125 values (p<0.0001). CD31 expression showed no prognostic survival value, but high hazard ratios were found for patients with high p53 expression (HR=2.313, p<0.0001). An interaction was found between p53 and stage of cancer, suggesting a prognostic impact of p53 in low-stage, but not in advanced-stage cancer. Conclusion: More than 5% of p53 tissue expression may predict shorter survival of ovarian cancer patients and may be useful for predicting the risk of disease progression in low-stage patients following primary surgery. CD31 has no strong prognostic value.